UNLIMITED TURBO LONG - UCB Stock

7AKOB

FRBNPP06P0U6

Market Closed - Euronext Paris 12:30:02 2024-07-12 pm EDT
2.94 ^EUR	-2.65%

Current month	+19.60%
1 month	+37.35%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)	Jun. 28	PU
UCB : Financial Reporting Document	Jun. 26	PU
UCB : Financial Reporting Document	Jun. 26	PU
UCB : epilepsy drug BRIVIACT(brivaracetam) approved in Japan for treatment of focal onset seizures	Jun. 26	PU

More news

Quotes 5-day view

Date	Price	Change
24-07-12	2.94	-2.65%
24-07-11	3.02	-2.89%
24-07-10	3.11	+4.36%
24-07-09	2.98	+5.30%
24-07-08	2.83	-2.08%

Real-time Euronext Paris

Last update July 12, 2024 at 12:30 pm EDT

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	UCB
Issuer	BNP Paribas
	7AKOB
ISIN	FRBNPP06P0U6
Date issued	2024-04-15
Strike	115.5 €
Maturity	Unlimited
Parity	10 : 1
Emission price	0.48 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	3.125 €
Lowest since issue	0.455 €
Spread	0.14 €
Spread %	4.65%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

144.6 EUR

Average target price

140.2 EUR

Spread / Average Target

-3.02%

Consensus